SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-022265
Filing Date
2023-02-15
Accepted
2023-02-15 10:42:00
Documents
14
Period of Report
2023-02-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm236640d1_8k.htm   iXBRL 8-K 32646
2 EXHIBIT 99.1 tm236640d1_ex99-1.htm EX-99.1 8406
  Complete submission text file 0001104659-23-022265.txt   275206

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA iber-20230215.xsd EX-101.SCH 3698
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE iber-20230215_def.xml EX-101.DEF 27779
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE iber-20230215_lab.xml EX-101.LAB 38282
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iber-20230215_pre.xml EX-101.PRE 26397
8 EXTRACTED XBRL INSTANCE DOCUMENT tm236640d1_8k_htm.xml XML 6772
Mailing Address 2005 MARKET STREET, SUITE 2030 PHILADELPHIA PA 19103
Business Address 2005 MARKET STREET, SUITE 2030 PHILADELPHIA PA 19103 267-765-3222
IBERE PHARMACEUTICALS (Filer) CIK: 0001835205 (see all company filings)

IRS No.: 981564986 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40119 | Film No.: 23634130
SIC: 6770 Blank Checks
Office of Real Estate & Construction